Coherus Biosciences Inc (CHRS) Stock: A Look at the Analyst Recommendations

CHRS has 36-month beta value of 0.51. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for CHRS is 106.17M, and currently, short sellers hold a 24.41% ratio of that float. The average trading volume of CHRS on April 03, 2024 was 4.32M shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

CHRS) stock’s latest price update

Coherus Biosciences Inc (NASDAQ: CHRS)’s stock price has decreased by -1.67 compared to its previous closing price of 2.40. However, the company has seen a 3.51% increase in its stock price over the last five trading sessions. Seeking Alpha reported 2024-03-20 that CHRS has sold Cimerli, a Lucentis biosimilar, to SDZNY. CHRS anti-IL-27 antibody, casdozokitug, shows promising results as part of a triple therapy in hepatocellular carcinoma, with an overall response rate of 38%. Numbers on market share point to a strong Q1’24 for Udenyca, which could increase the market’s confidence that CHRS can offset lost revenues from the Cimerli sale.

CHRS’s Market Performance

CHRS’s stock has risen by 3.51% in the past week, with a monthly drop of -2.07% and a quarterly drop of -29.13%. The volatility ratio for the week is 5.52% while the volatility levels for the last 30 days are 8.29% for Coherus Biosciences Inc The simple moving average for the last 20 days is 2.08% for CHRS stock, with a simple moving average of -28.78% for the last 200 days.

Analysts’ Opinion of CHRS

Many brokerage firms have already submitted their reports for CHRS stocks, with Robert W. Baird repeating the rating for CHRS by listing it as a “Outperform.” The predicted price for CHRS in the upcoming period, according to Robert W. Baird is $11 based on the research report published on November 17, 2023 of the previous year 2023.

Citigroup gave a rating of “Buy” to CHRS, setting the target price at $12 in the report published on July 24th of the previous year.

CHRS Trading at -1.04% from the 50-Day Moving Average

After a stumble in the market that brought CHRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.72% of loss for the given period.

Volatility was left at 8.29%, however, over the last 30 days, the volatility rate increased by 5.52%, as shares surge +3.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.28% lower at present.

During the last 5 trading sessions, CHRS rose by +3.51%, which changed the moving average for the period of 200-days by -55.97% in comparison to the 20-day moving average, which settled at $2.32. In addition, Coherus Biosciences Inc saw -29.13% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CHRS starting from Lanfear Dennis M, who sale 223,100 shares at the price of $2.02 back on Nov 22 ’23. After this action, Lanfear Dennis M now owns 731,693 shares of Coherus Biosciences Inc, valued at $449,770 using the latest closing price.

Stock Fundamentals for CHRS

Current profitability levels for the company are sitting at:

  • -0.79 for the present operating margin
  • 0.38 for the gross margin

The net margin for Coherus Biosciences Inc stands at -0.92. The total capital return value is set at -0.68.

Based on Coherus Biosciences Inc (CHRS), the company’s capital structure generated 1.69 points at debt to capital in total, while cash flow to debt ratio is standing at -0.37. The debt to equity ratio resting at -2.46. The interest coverage ratio of the stock is -10.13.

Currently, EBITDA for the company is -189.41 million with net debt to EBITDA at -1.91. When we switch over and look at the enterprise to sales, we see a ratio of 2.49. The receivables turnover for the company is 0.99for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.43.

Conclusion

To put it simply, Coherus Biosciences Inc (CHRS) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts